Perphenazine

Depression, Generalized Anxiety Disorder, Schizophrenia + 8 more

Treatment

12 FDA approvals

20 Active Studies for Perphenazine

What is Perphenazine

Perphenazine

The Generic name of this drug

Treatment Summary

An antipsychotic medication with effects similar to that of chlorpromazine, a medicine used to treat psychosis.

Perphenazine

is the brand name

Perphenazine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Perphenazine

Perphenazine

1987

153

Approved as Treatment by the FDA

Perphenazine, also known as Perphenazine, is approved by the FDA for 12 uses like Anxiety and Generalized Anxiety Disorder .

Anxiety

Used to treat severe Anxiety in combination with Amitriptyline

Generalized Anxiety Disorder

Used to treat Anxiety in combination with Amitriptyline

Mental Depression

Used to treat moderate Depressed mood in combination with Amitriptyline

Depression

Used to treat Depression in combination with Amitriptyline

Mental Depression

Used to treat severe Depressed mood in combination with Amitriptyline

severe Nausea and vomiting

moderate Anxiety

Used to treat moderate Anxiety in combination with Amitriptyline

Schizophrenia

Helps manage Schizophrenia

Chronic Physical Illness

Used to treat Chronic Physical Illness in combination with Amitriptyline

Nausea

severe agitation

Used to treat severe agitation in combination with Amitriptyline

moderate Agitation

Used to treat moderate Agitation in combination with Amitriptyline

Effectiveness

How Perphenazine Affects Patients

Perphenazine is a member of the phenothiazine class of drugs, which work on the central nervous system and block the action of dopamine in the brain. It is much more powerful than other similar drugs, and is used as a highly effective antipsychotic. In terms of side effects, Perphenazine is about as likely and severe to cause early and late extrapyramidal side effects as Haloperidol.

How Perphenazine works in the body

Perphenazine blocks the activity of dopamine D1 and D2 receptors. This helps control nausea and vomiting by preventing the dopamine neurotransmitter from stimulating the receptors in the areas of the brain responsible for these symptoms. Perphenazine also binds to alpha andrenergic receptors, which are responsible for activating a cell signaling pathway.

When to interrupt dosage

The proposed measure of Perphenazine is contingent upon the determined condition, like Generalized Anxiety Disorder, moderate Agitation and Depression. The degree of dosage varies as per the approach of delivery (e.g. Syrup - Oral or Tablet, sugar coated - Oral) featured in the table below.

Condition

Dosage

Administration

Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Nausea

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Anxiety

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Chronic Physical Illness

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

moderate Anxiety

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

moderate Agitation

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Mental Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Mental Depression

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Generalized Anxiety Disorder

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Schizophrenia

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

severe agitation

, 2.0 mg, 4.0 mg, 8.0 mg, 16.0 mg, 3.0 mg, 5.0 mg/mL, 2.0 mg/mL, 3.2 mg/mL, 16.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Syrup, Syrup - Oral

Warnings

Perphenazine has seven contraindications, consequently it should not be taken when any of the conditions specified in the following table occur.

Perphenazine Contraindications

Condition

Risk Level

Notes

large dose of CNS depressants

Do Not Combine

Brain Injuries

Do Not Combine

Liver Damage

Do Not Combine

Coma

Do Not Combine

Disease

Do Not Combine

greatly obtunded patients

Do Not Combine

Bone Marrow

Do Not Combine

There are 20 known major drug interactions with Perphenazine.

Common Perphenazine Drug Interactions

Drug Name

Risk Level

Description

Amisulpride

Major

Perphenazine may increase the antipsychotic activities of Amisulpride.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Perphenazine.

Azelastine

Major

Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Perphenazine.

Deutetrabenazine

Major

The risk or severity of adverse effects can be increased when Perphenazine is combined with Deutetrabenazine.

Perphenazine Toxicity & Overdose Risk

Signs of overdosing on amitriptyline include stupor or unconsciousness, and in some cases, seizures in children. Patients may not regain consciousness for up to two days. The lowest toxic dose for rats is 318mg/kg, and 64mg/kg for mice.

image of a doctor in a lab doing drug, clinical research

Perphenazine Novel Uses: Which Conditions Have a Clinical Trial Featuring Perphenazine?

985 active investigations are currently assessing the potential of Perphenazine to palliate moderate Agitation, Anxiety and Nausea.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

181 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3

Schizophrenia

97 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

moderate Anxiety

0 Actively Recruiting

Nausea

0 Actively Recruiting

Anxiety

0 Actively Recruiting

moderate Agitation

0 Actively Recruiting

Chronic Physical Illness

1 Actively Recruiting

Not Applicable

severe agitation

0 Actively Recruiting

Depression

304 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Mental Depression

0 Actively Recruiting

Mental Depression

0 Actively Recruiting

Perphenazine Reviews: What are patients saying about Perphenazine?

5

Patient Review

12/28/2020

Perphenazine for Schizophrenia

I was originally prescribed 2mg of this medication, but I still felt like evil spirits were touching me. My doctor then increased the dosage to 4mg and then 6mg, and I no longer have those sensations. I am a bit tired during the day, but overall I'm much happier now.

5

Patient Review

8/26/2015

Perphenazine for Schizophrenia

I've tried a lot of different medications, but this is the best one I've found so far. It helps me manage my symptoms without making me feel sedated or like a zombie. Life is more worth living with this medication.

5

Patient Review

4/2/2016

Perphenazine for Schizophrenia

This medication is highly effective for me with very few side effects. I take it at night to avoid feeling sedated or dizzy during the day.

5

Patient Review

2/27/2010

Perphenazine for Mental Disorder with Loss of Normal Personality & Reality

5

Patient Review

4/16/2011

Perphenazine for Schizophrenia

This pill has been helping me since I started taking it.

4.7

Patient Review

12/22/2019

Perphenazine for Schizophrenia

This medication has been a big help to me in managing my shizoaffective disorder. It's effective at quieting the voices I hear and also helped with negative thinking.

4.3

Patient Review

12/12/2013

Perphenazine for Mental Disorder with Loss of Normal Personality & Reality

This medication has been a life-saver for me. I had been experiencing insomnia for 4 days and my meds were adjusted from Abilify to perphenazine. After 2 weeks all of my symptoms were relieved and I can sleep 7-8 hours every night.

4.3

Patient Review

10/1/2010

Perphenazine for Mental Disorder with Loss of Normal Personality & Reality

I've tried a lot of different treatments for my bipolar disorder, and this one seems to be working better than anything else I've tried. I'm feeling more stable and less suicidal, which is a huge relief.

4.3

Patient Review

3/26/2010

Perphenazine for Schizophrenia

Perphenazine was effective for me, but unfortunately caused permanent impotence.

4.3

Patient Review

1/25/2011

Perphenazine for Schizophrenia

This drug has been really helpful for me in terms of organization and slowing down my thoughts. The only downside is that I sometimes feel dizzy when I stand up too quickly, but it's not a huge issue.

4.3

Patient Review

1/10/2012

Perphenazine for Mental Disorder with Loss of Normal Personality & Reality

This drug has been effective in silencing the voices I hear as a result of my bipolar II and PTSD. When I first started taking it, I experienced headaches; however, those went away after continued use.

3.3

Patient Review

6/7/2010

Perphenazine for Mental Disorder with Loss of Normal Personality & Reality

My doctor prescribed this medication for my insomnia, but I found it actually made it harder to sleep.

3

Patient Review

3/10/2011

Perphenazine for Schizophrenia

Many of the symptoms are similar to those of ADHD, such as a lack of organization and follow-through, forgetfulness, and difficulty sleeping regularly.

2.7

Patient Review

4/17/2013

Perphenazine for Mental Disorder with Loss of Normal Personality & Reality

ADHD is my diagnosis and the doctor prescribed this to help me focus better in conjunction with Adderall. I haven't seen much of a difference yet.

2.7

Patient Review

12/30/2009

Perphenazine for Schizophrenia

2

Patient Review

4/26/2010

Perphenazine for Mental Disorder with Loss of Normal Personality & Reality

After being taken off of my other medications and prescribed perphenazine, I've been feeling so much better. It's been six weeks and I can definitely say that this medication has helped to level out my hypomania and depression.

Patient Q&A Section about perphenazine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug perphenazine used for?

"Perphenazine is used to treat symptoms of schizophrenia, such as disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions. Perphenazine is also used to control severe nausea and vomiting in adults."

Answered by AI

Is perphenazine good for anxiety?

"Perphenazine is an effective medication for patients with varying degrees of anxiety and agitation, from mild tension or hyperactivity to severe psychosis or psychomotor hyperactivity."

Answered by AI

Is perphenazine a sedative?

"Perphenazine has properties that help to calm patients and reduce anxiety, making the drug useful for treating psychotic patients who are agitated."

Answered by AI

Is perphenazine used for depression?

"This medicine is used to treat depression that may be accompanied by anxiety or agitation. It is also used to treat schizophrenia."

Answered by AI

Clinical Trials for Perphenazine

Have you considered Perphenazine clinical trials?

We made a collection of clinical trials featuring Perphenazine, we think they might fit your search criteria.
Go to Trials
Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Have you considered Perphenazine clinical trials?

We made a collection of clinical trials featuring Perphenazine, we think they might fit your search criteria.
Go to Trials
Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Fort Bend ISD in Sugar Land, United States.

Wellbeing Interventions for Anxiety

10 - 20
All Sexes
Sugar Land, TX

The goal of this clinical trial is to learn if psychology and music based interventions can impact anxiety and overall wellbeing in adolescents enrolled in choral music classes. The main questions it aims to answer are: Do specific psychology and music based breathing interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based performance anxiety reduction interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based emotion regulation interventions impact anxiety and overall wellbeing in adolescents? Researchers will compare results of pre-test data, post-test data, qualitative interviews, and surveys of adult choral directors to see if there is a measurable impact on adolescent anxiety and overall wellbeing. Participants will: * Use box breathing during choral music warm-ups to connect choral breathing to breathing for anxiety reduction * Use "magnify" technique to compare cognitive distortions regarding an upcoming performance that may cause anxiety to the most likely realistic outcome * Use emotion regulation through song lyrics technique to connect lyrics of choral music repertoire to participants experienced emotions

Waitlist Available
Has No Placebo

Fort Bend ISD

Jane Kuehne, PhD

Have you considered Perphenazine clinical trials?

We made a collection of clinical trials featuring Perphenazine, we think they might fit your search criteria.
Go to Trials